Linatab M 2.5/500 Tablet

What is Linatab M?

Linatab M is a fixed-dose combination tablet manufactured by Incepta Pharmaceuticals Ltd., combining the DPP-4 inhibitor Linagliptin with the biguanide Metformin. It offers dual-action blood glucose control for type 2 diabetes in a single tablet, reducing pill burden compared to taking each medicine separately. The 2.5/500 strength is typically used as a starting combination dose.

Generic Name and Composition

Each tablet contains 2.5 mg of Linagliptin and 500 mg of Metformin Hydrochloride.

Indications

• Type 2 diabetes mellitus in patients not adequately controlled on metformin alone
• Type 2 diabetes mellitus as initial combination therapy in newly diagnosed patients requiring both agents
• Used as an adjunct to diet and exercise to improve glycemic control

How It Works — Mechanism of Action

Linagliptin inhibits the DPP-4 enzyme, increasing active incretin hormone levels that stimulate glucose-dependent insulin release and suppress glucagon secretion. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity. Together, these complementary mechanisms provide more comprehensive blood glucose control than either agent alone.

Dosage and Administration

• Dosage is individualized by a physician, often starting at this lower-strength combination before titrating upward if needed.
• Typically taken twice daily with meals to minimize gastrointestinal side effects.
• Swallow the tablet whole with water — do not crush or chew unless instructed otherwise.
• If a dose is missed, take it with the next meal; do not double up.

Side Effects

Common: Nausea, diarrhea, abdominal discomfort, metallic taste, nasopharyngitis.

Uncommon: Hypoglycemia (mainly when combined with sulfonylureas or insulin), reduced appetite, vitamin B12 deficiency with long-term use.

Rare: Lactic acidosis, pancreatitis, severe allergic reactions (angioedema, urticaria, anaphylaxis), bullous pemphigoid.

Drug Interactions

Increased lactic acidosis risk: Iodinated contrast media, excessive alcohol intake.

Increased hypoglycemia risk: Sulfonylureas, insulin.

May affect blood glucose control: Corticosteroids, diuretics, strong CYP3A4/P-glycoprotein inducers (e.g., rifampicin).

Contraindications

• Severe renal impairment
• Known hypersensitivity to linagliptin, metformin, or any excipient
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis
• Conditions predisposing to tissue hypoxia (severe heart failure, respiratory failure, recent myocardial infarction)

Pregnancy and Lactation

Safety of this combination in pregnancy and breastfeeding has not been firmly established; insulin is generally preferred for glycemic control during pregnancy. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

Precautions and Warnings

• Temporarily discontinue before procedures involving iodinated contrast media, as advised by your physician.
• Use with caution in patients with reduced kidney function; periodic renal function monitoring is recommended.
• Watch for symptoms of pancreatitis (persistent severe abdominal pain) and discontinue promptly if suspected.
• Seek immediate medical attention for symptoms of lactic acidosis (unusual muscle pain, difficulty breathing, abdominal pain, severe tiredness).
• Avoid excessive alcohol intake.

Overdose

Overdose may lead to lactic acidosis (from the metformin component), presenting with malaise, abdominal pain, and difficulty breathing — a medical emergency requiring immediate hospital care, potentially including hemodialysis. Significant hypoglycemia from linagliptin alone is unlikely.

Storage Instructions

• Store below 30°C in a cool, dry place, away from direct sunlight and moisture.
• Keep out of reach of children.
• Do not use after the expiry date printed on the pack.

Frequently Asked Questions

Q1: Why is Linatab M taken twice daily?
The metformin component is typically dosed twice daily with meals to maintain steady blood levels and minimize gastrointestinal side effects.

Q2: Is 2.5/500 a common starting dose?
Yes, this lower-strength combination is often used as an initial dose, with your physician titrating the metformin component upward as needed and tolerated.

Q3: Will Linatab M cause low blood sugar?
The risk of hypoglycemia is low when used alone, since neither linagliptin nor metformin independently stimulates excess insulin release; risk increases when combined with sulfonylureas or insulin.

Q4: How does Linatab M 2.5/500 differ from Linatab M 2.5/850 or 2.5/1000?
All contain the same 2.5mg linagliptin dose; the metformin component differs (500mg, 850mg, or 1000mg), allowing the physician to titrate the metformin dose to the patient's tolerability and glycemic needs.

Medical Disclaimer

This product is available by prescription only (Rx) and should be used under medical supervision. The information provided is for educational purposes and does not replace professional medical advice. Always consult a registered physician before starting, stopping, or changing any medication. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.